213 related articles for article (PubMed ID: 23380368)
1. Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression.
Shafi AA; Cox MB; Weigel NL
Steroids; 2013 Jun; 78(6):548-54. PubMed ID: 23380368
[TBL] [Abstract][Full Text] [Related]
2. Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors.
Gillis JL; Selth LA; Centenera MM; Townley SL; Sun S; Plymate SR; Tilley WD; Butler LM
Oncotarget; 2013 May; 4(5):691-704. PubMed ID: 23674566
[TBL] [Abstract][Full Text] [Related]
3. Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer.
Moon SJ; Jeong BC; Kim HJ; Lim JE; Kim HJ; Kwon GY; Jackman JA; Kim JH
Theranostics; 2021; 11(2):958-973. PubMed ID: 33391515
[No Abstract] [Full Text] [Related]
4. Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells.
Krause WC; Shafi AA; Nakka M; Weigel NL
Int J Biochem Cell Biol; 2014 Sep; 54():49-59. PubMed ID: 25008967
[TBL] [Abstract][Full Text] [Related]
5. Effect of geldanamycin on androgen receptor function and stability.
Vanaja DK; Mitchell SH; Toft DO; Young CY
Cell Stress Chaperones; 2002 Jan; 7(1):55-64. PubMed ID: 11894840
[TBL] [Abstract][Full Text] [Related]
6. Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms.
Centenera MM; Carter SL; Gillis JL; Marrocco-Tallarigo DL; Grose RH; Tilley WD; Butler LM
Endocr Relat Cancer; 2015 Oct; 22(5):805-18. PubMed ID: 26187127
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of ID4 promotes a CRPC phenotype with constitutive AR activation through FKBP52.
Joshi JB; Patel D; Morton DJ; Sharma P; Zou J; Hewa Bostanthirige D; Gorantla Y; Nagappan P; Komaragiri SK; Sivils JC; Xie H; Palaniappan R; Wang G; Cox MB; Chaudhary J
Mol Oncol; 2017 Apr; 11(4):337-357. PubMed ID: 28252832
[TBL] [Abstract][Full Text] [Related]
8. Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells.
Ferraldeschi R; Welti J; Powers MV; Yuan W; Smyth T; Seed G; Riisnaes R; Hedayat S; Wang H; Crespo M; Nava Rodrigues D; Figueiredo I; Miranda S; Carreira S; Lyons JF; Sharp S; Plymate SR; Attard G; Wallis N; Workman P; de Bono JS
Cancer Res; 2016 May; 76(9):2731-42. PubMed ID: 27197266
[TBL] [Abstract][Full Text] [Related]
9. Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression.
He S; Zhang C; Shafi AA; Sequeira M; Acquaviva J; Friedland JC; Sang J; Smith DL; Weigel NL; Wada Y; Proia DA
Int J Oncol; 2013 Jan; 42(1):35-43. PubMed ID: 23152004
[TBL] [Abstract][Full Text] [Related]
10. Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer.
Lamoureux F; Thomas C; Yin MJ; Fazli L; Zoubeidi A; Gleave ME
Eur Urol; 2014 Jul; 66(1):145-55. PubMed ID: 24411988
[TBL] [Abstract][Full Text] [Related]
11. Role of androgen receptor splice variants, their clinical relevance and treatment options.
Wach S; Taubert H; Cronauer M
World J Urol; 2020 Mar; 38(3):647-656. PubMed ID: 30659302
[TBL] [Abstract][Full Text] [Related]
12. The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells.
Saporita AJ; Ai J; Wang Z
Prostate; 2007 Apr; 67(5):509-20. PubMed ID: 17221841
[TBL] [Abstract][Full Text] [Related]
13. Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells.
De Leon JT; Iwai A; Feau C; Garcia Y; Balsiger HA; Storer CL; Suro RM; Garza KM; Lee S; Kim YS; Chen Y; Ning YM; Riggs DL; Fletterick RJ; Guy RK; Trepel JB; Neckers LM; Cox MB
Proc Natl Acad Sci U S A; 2011 Jul; 108(29):11878-83. PubMed ID: 21730179
[TBL] [Abstract][Full Text] [Related]
14. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.
Hu R; Lu C; Mostaghel EA; Yegnasubramanian S; Gurel M; Tannahill C; Edwards J; Isaacs WB; Nelson PS; Bluemn E; Plymate SR; Luo J
Cancer Res; 2012 Jul; 72(14):3457-62. PubMed ID: 22710436
[TBL] [Abstract][Full Text] [Related]
15. Melatonin Inhibits Androgen Receptor Splice Variant-7 (AR-V7)-Induced Nuclear Factor-Kappa B (NF-κB) Activation and NF-κB Activator-Induced AR-V7 Expression in Prostate Cancer Cells: Potential Implications for the Use of Melatonin in Castration-Resistant Prostate Cancer (CRPC) Therapy.
Liu VWS; Yau WL; Tam CW; Yao KM; Shiu SYW
Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28561752
[TBL] [Abstract][Full Text] [Related]
16. Multimodal actions of the phytochemical sulforaphane suppress both AR and AR-V7 in 22Rv1 cells: Advocating a potent pharmaceutical combination against castration-resistant prostate cancer.
Khurana N; Kim H; Chandra PK; Talwar S; Sharma P; Abdel-Mageed AB; Sikka SC; Mondal D
Oncol Rep; 2017 Nov; 38(5):2774-2786. PubMed ID: 28901514
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal.
Chan SC; Li Y; Dehm SM
J Biol Chem; 2012 Jun; 287(23):19736-49. PubMed ID: 22532567
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a Small-Molecule Inhibitor Targeting the Androgen Receptor N-Terminal Domain for Castration-Resistant Prostate Cancer.
Yi Q; Liu W; Seo JH; Su J; Alaoui-Jamali MA; Luo J; Lin R; Wu JH
Mol Cancer Ther; 2023 May; 22(5):570-582. PubMed ID: 37139712
[TBL] [Abstract][Full Text] [Related]
19. Effect of the hsp90 inhibitor geldanamycin on androgen response of prostate cancer under hypoxic conditions.
Suzuki Y; Kondo Y; Hara S; Kimata R; Nishimura T
Int J Urol; 2010 Mar; 17(3):281-5. PubMed ID: 20409220
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Targeting of the FKBP52 Co-Chaperone in Steroid Hormone Receptor-Regulated Physiology and Disease.
Guy NC; Garcia YA; Cox MB
Curr Mol Pharmacol; 2015; 9(2):109-25. PubMed ID: 25986565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
